Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand - PubMed (original) (raw)
Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand
T Takahashi et al. Cell. 1994.
Abstract
Mice homozygous for lpr (lymphoproliferation) or gld (generalized lymphoproliferative disease) develop lymphadenopathy and suffer from autoimmune disease. The lpr mice have a mutation in a cell-surface protein, Fas, that mediates apoptosis. Fas ligand (FasL) is a tumor necrosis factor (TNF)-related type II membrane protein and binds to Fas. Here, mouse Fasl gene was isolated and localized to the gld region of mouse chromosome 1. Activated splenocytes from gld mice express Fasl mRNA. However, FasL in gld mice carries a point mutation in the C-terminal region, which is highly conserved among members of the TNF family. The recombinant gld FasL expressed in COS cells could not induce apoptosis in cells expressing Fas. These results indicate that lpr and gld are mutations in Fas and Fasl, respectively, and suggest important roles of the Fas system in development of T cells as well as cytotoxic T lymphocyte-mediated cytotoxicity.
Similar articles
- Constitutive activation of the Fas ligand gene in mouse lymphoproliferative disorders.
Watanabe D, Suda T, Hashimoto H, Nagata S. Watanabe D, et al. EMBO J. 1995 Jan 3;14(1):12-8. doi: 10.1002/j.1460-2075.1995.tb06970.x. EMBO J. 1995. PMID: 7530197 Free PMC article. - The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster.
Lynch DH, Watson ML, Alderson MR, Baum PR, Miller RE, Tough T, Gibson M, Davis-Smith T, Smith CA, Hunter K, et al. Lynch DH, et al. Immunity. 1994 May;1(2):131-6. doi: 10.1016/1074-7613(94)90106-6. Immunity. 1994. PMID: 7889405 - Fas and Fas ligand: lpr and gld mutations.
Nagata S, Suda T. Nagata S, et al. Immunol Today. 1995 Jan;16(1):39-43. doi: 10.1016/0167-5699(95)80069-7. Immunol Today. 1995. PMID: 7533498 Review. - Cellular interactions in the lpr and gld models of systemic autoimmunity.
Sobel ES. Sobel ES. Adv Dent Res. 1996 Apr;10(1):76-80. doi: 10.1177/08959374960100011601. Adv Dent Res. 1996. PMID: 8934931 Review.
Cited by
- Managing macrophages in rheumatoid arthritis by reform or removal.
Li J, Hsu HC, Mountz JD. Li J, et al. Curr Rheumatol Rep. 2012 Oct;14(5):445-54. doi: 10.1007/s11926-012-0272-4. Curr Rheumatol Rep. 2012. PMID: 22855296 Free PMC article. Review. - The role of CD95 and CD95 ligand in cancer.
Peter ME, Hadji A, Murmann AE, Brockway S, Putzbach W, Pattanayak A, Ceppi P. Peter ME, et al. Cell Death Differ. 2015 Apr;22(4):549-59. doi: 10.1038/cdd.2015.3. Epub 2015 Feb 6. Cell Death Differ. 2015. PMID: 25656654 Free PMC article. Review. - Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease.
Anderton H, Wicks IP, Silke J. Anderton H, et al. Nat Rev Rheumatol. 2020 Sep;16(9):496-513. doi: 10.1038/s41584-020-0455-8. Epub 2020 Jul 8. Nat Rev Rheumatol. 2020. PMID: 32641743 Review. - Cutting edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent manner.
Bossaller L, Chiang PI, Schmidt-Lauber C, Ganesan S, Kaiser WJ, Rathinam VA, Mocarski ES, Subramanian D, Green DR, Silverman N, Fitzgerald KA, Marshak-Rothstein A, Latz E. Bossaller L, et al. J Immunol. 2012 Dec 15;189(12):5508-12. doi: 10.4049/jimmunol.1202121. Epub 2012 Nov 9. J Immunol. 2012. PMID: 23144495 Free PMC article. - Autoimmunity: twenty years in the Fas lane.
Ramaswamy M, Siegel RM. Ramaswamy M, et al. J Immunol. 2012 Dec 1;189(11):5097-100. doi: 10.4049/jimmunol.1202833. J Immunol. 2012. PMID: 23169861 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous